2 completed, 2 recruiting, 1 terminated. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow AL001: new trials by email Literature Review of AL001 trials Research Report on AL001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder AL001, Lithium carbonate - Bipolar I Disorder | Phase 1 / Phase 2 | Recruiting | Alzamend Neuro, Inc. | 20 | 2026-05-11 | 2026-07-28 |
| Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer Cadonilimab, Anlotinib, Granulocyte-Macrophage Colony-Stimulating Factor - Cervical Cancer | Phase 2 | Recruiting | Zhongnan Hospital | 35 | 2023-02-16 | 2024-04-19 |
| Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects AL001, Placebo - Alzheimer's Disease, Healthy Non-elderly and Elderly Adults | Phase 1 / Phase 2 | Completed | Alzamend Neuro, Inc. | 65 | 2022-05-04 | 2025-05-14 |
| A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS AL001, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Terminated | Alector Inc. | 5 | 2021-09-02 | 2025-06-18 |
| A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) AL001 - Frontotemporal Dementia | Phase 2 | Completed | Alector Inc. | 33 | 2019-09-27 | 2025-12-05 |
Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · Frontotemporal Dementia (1) · Uterine Cervical Neoplasms (1)
Alector Inc. (2) · Alzamend Neuro, Inc. (2) · Zhongnan Hospital (1)
United States (4) · Canada (2) · China (1) · Germany (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
Eric Sicard, MD (1) · Hui Qiu, Ph.D. (1) · Peter Ljubenkov, MD (1) · Sabrina Paganoni, MD (1)